News | March 17, 2026
BioDuro and Cenra API Solutions forge global API manufacturing joint venture in Taiwan
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test
The trial will enroll up to 42 patients in Finland across four cohorts
There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
The product is bioequivalent and therapeutically equivalent to Fresenius Kabi’s reference drug (NDA 212832)
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
